REGENERON CELL MEDICINES Trademark
Trademark Overview
On Thursday, July 4, 2024, a trademark application was filed for REGENERON CELL MEDICINES with the United States Patent and Trademark Office. The USPTO has given the REGENERON CELL MEDICINES trademark a serial number of 98625063. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, April 21, 2025. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The REGENERON CELL MEDICINES trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations and substances for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents and biological preparations, namely, viral vectors, all for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer
Pharmaceutical research and development services
General Information
| Serial Number | 98625063 |
| Word Mark | REGENERON CELL MEDICINES |
| Filing Date | Thursday, July 4, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Monday, April 21, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical preparations and substances for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents and biological preparations, namely, viral vectors, all for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer |
| NOT AVAILABLE | "CELL MEDICINES" |
| Goods and Services | Pharmaceutical research and development services |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 4, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 4, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Regeneron Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Tarrytown, NY 10591 |
Trademark Events
| Event Date | Event Description |
| Thursday, July 4, 2024 | NEW APPLICATION ENTERED |
| Tuesday, January 14, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, January 29, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 29, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 21, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, April 21, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, April 21, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 16, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, January 29, 2025 | NON-FINAL ACTION E-MAILED |
